Also, HUD reported the number of chronically homeless people (persons with severe disabilities and long homeless histories) decreased one percent between 2009 and 2010, from 110,917 to 109,812. Since 2007 this number had decreased by 11 percent. This was mostly due to the expansion of permanent supportive housing programs.The change in numbers has occurred due to the prevalence of homelessness in local communities rather than other changes. According to HUDs July 2010 Homeless Assessment Report to Congress, more than 1.59 million people spent at least one night in an emergency shelter or transitional housing program during the 2010 reporting period, a 2.2 percent increase from 2009. Most users of homeless shelters used only an emergency shelter, while 17 percent used only transitional housing, and less than 5 percent used both during the reporting period. Since 2007, the annual number of those using homeless shelters in cities has decreased from 1.22 million to 1.02 million, a 17 percent decrease. The number of persons using homeless shelters in suburban and rural areas increased 57 percent, from 367,000 to 576,000. In the U.S., the federal governments HUD agency has required federally-funded organizations to use a computer tracking system for homeless people and their statistics, called HMIS (Homeless Management Information System). There has been some opposition to this kind of tracking by privacy advocacy groups, such as EPIC.However, HUD considers its reporting techniques to be reasonably accurate for homeless in shelters and programs in its Annual Homeless Assessment Report to Congress.
Drospirenone/estetrol, sold under the brand name Nextstellis among others, is a fixed-dose combination medication containing drospirenone, a progestin, and estetrol, an estrogen, which is used as a combined birth control pill for the prevention of pregnancy in women. It is taken by mouth.It was approved for medical use in Canada in March 2021, and in the United States in April 2021. Medical uses
Drospirenone/estetrol is used as a combined birth control pill to prevent pregnancy in women. Side effects
Estetrol-containing birth control pills, similarly to estradiol-containing birth control pills, may have a lower risk of venous thromboembolism (VTE) than ethinylestradiol-containing birth control pills based on studies of coagulation. However, it is likely that another decade will be required before post-marketing epidemiological studies of VTE incidence with these birth control pills are completed and able to confirm this. Pharmacology
Pharmacodynamics
Drospirenone/estetrol has a much lower impact on liver protein synthesis, including of sex hormone-binding globulin, angiotensinogen, and coagulation factors, than does ethinylestradiol/drospirenone. Society and culture
Legal status
Drospirenone/estetrol is approved for the use of hormonal contraception in the European Union, the United States, and Canada. Brand names
Drospirenone/estetrol in sold under the brand names Nexstellis, Drovelis, and Lydisilka. See also
Birth control pill formulations
List of combined sex-hormonal preparations § Estrogens and progestogens

References
External links
"Drospirenone". Drug Information Portal. U.S. National Library of Medicine. "Estetrol". Drug Information Portal. U.S. National Library of Medicine.